Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia
Oral blarcamesine delivers long-term benefit in early AD
24 Oct 2025
bởiAudrey Abella
Findings from the phase IIb/III ATTENTION-AD study reflect the continued benefit of oral blarcamesine in individuals with early Alzheimer’s disease (AD) after receiving the drug continuously for up to 4 years.
Oral blarcamesine delivers long-term benefit in early AD
24 Oct 2025
Infant antibiotic use ups risks of asthma, later infections
23 Oct 2025
bởiStephen Padilla
Early use of antibiotics among children may lead to several health concerns, including asthma and later infections during childhood years, suggests a study.
Infant antibiotic use ups risks of asthma, later infections
23 Oct 2025
Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo
22 Oct 2025
bởiStephen Padilla
Treatment with the Janus kinase (JAK) 1 inhibitor povorcitinib results in significant repigmentation of the body and face in adult patients with extensive nonsegmental vitiligo (NSV), with an acceptable safety profile, through 52 weeks, reports a phase II study.
